A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication.
about
Stem-cell-based gene therapy for HIV infectionRecent Advances in Lentiviral Vaccines for HIV-1 InfectionCombination of nanoparticle-based therapeutic vaccination and transient ablation of regulatory T cells enhances anti-viral immunity during chronic retroviral infectionCurrent Advances in Virus-Like Particles as a Vaccination Approach against HIV InfectionEvaluating the efficacy of therapeutic HIV vaccines through analytical treatment interruptionsHIV therapeutic vaccines: moving towards a functional cureDendritic Cell-Based Immunotherapies to Fight HIV: How Far from a Success Story? A Systematic Review and Meta-AnalysisT-Regulatory Cells and Vaccination "Pay Attention and Do Not Neglect Them": Lessons from HIV and Cancer Vaccine TrialsDNA/MVA Vaccination of HIV-1 Infected Participants with Viral Suppression on Antiretroviral Therapy, followed by Treatment Interruption: Elicitation of Immune Responses without Control of Re-Emergent VirusImmune responses during spontaneous control of HIV and AIDS: what is the hope for a cure?Developments in HIV-1 immunotherapy and therapeutic vaccination.Mucosal SIV Vaccines Comprising Inactivated Virus Particles and Bacterial Adjuvants Induce CD8(+) T-Regulatory Cells that Suppress SIV-Positive CD4(+) T-Cell Activation and Prevent SIV Infection in the Macaque Model.Immunologic strategies for HIV-1 remission and eradication.Host genomic HIV restriction factors modulate the response to dendritic cell-based treatment against HIV-1HIV-1 DNA predicts disease progression and post-treatment virological control.Dendritic cells in progression and pathology of HIV infection.Autologous aldrithiol-2-inactivated HIV-1 combined with polyinosinic-polycytidylic acid-poly-L-lysine carboxymethylcellulose as a vaccine platform for therapeutic dendritic cell immunotherapySynthetic consensus HIV-1 DNA induces potent cellular immune responses and synthesis of granzyme B, perforin in HIV infected individualsDecreased HIV-specific T-regulatory responses are associated with effective DC-vaccine induced immunityThe need for treatment interruption studies and biomarker identification in the search for an HIV cure.HIV-1 Reservoir Dynamics after Vaccination and Antiretroviral Therapy Interruption Are Associated with Dendritic Cell Vaccine-Induced T Cell Responses.Specific Elimination of Latently HIV-1 Infected Cells Using HIV-1 Protease-Sensitive Toxin Nanocapsules.HIV-specific CD8⁺ T cells and HIV eradicationParticipation in HIV cure-related research: a scoping review of the proxy literature and implications for future researchImmunization of HIV-1-Infected Persons With Autologous Dendritic Cells Transfected With mRNA Encoding HIV-1 Gag and Nef: Results of a Randomized, Placebo-Controlled Clinical Trial.Therapeutic Vaccination With Dendritic Cells Loaded With Autologous HIV Type 1-Infected Apoptotic Cells.Dendritic Cell Immunotherapy for HIV-1 Infection Using Autologous HIV-1 RNA: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.Effective Cytotoxic T Lymphocyte Targeting of Persistent HIV-1 during Antiretroviral Therapy Requires Priming of Naive CD8+ T CellsHIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trialBrief Report: Relationship Among Viral Load Outcomes in HIV Treatment Interruption Trials.Non-immunogenicity of overlapping gag peptides pulsed on autologous cells after vaccination of HIV infected individuals.Human dendritic cell subsets in vaccination.Dendritic cell dysregulation during HIV-1 infection.Dendritic cell based vaccines for HIV infection: the way ahead.Immunodiscordant responses to HAART--mechanisms and consequences.A cure for AIDS: a matter of timing?CD4 T cell defects in the aged: causes, consequences and strategies to circumvent.Future considerations for dendritic cell immunotherapy against chronic viral infections.A cure for HIV: is it in sight?Targeting human dendritic cells in situ to improve vaccines.
P2860
Q24607667-EF032EA5-BC14-4C5E-9C36-9DEBC8F0F9F0Q26742169-AA9D1011-CAF1-4F74-9A24-FE778BFECCA7Q26748624-DB880987-6F0D-4B97-B854-18301C214637Q26775082-5FE96EC5-793A-4CA8-ACE7-A500CF750845Q26777442-71B689C0-0F24-4BEC-8832-89BE3823467CQ27002180-C6BB64A3-1694-40E7-8AB6-05B8FE53A067Q28070121-B6896FE7-F3B5-456E-975F-7BC5957403B8Q28074437-F5258818-8A89-4AF5-9865-03541C04902BQ28554534-91070FB8-EF39-4762-B5B1-D1147C2C6A9FQ30362489-097535DB-114F-4641-9687-1A1FA128CA4CQ30364312-5C928390-7823-4022-A99A-BE70F43A439CQ33820903-2BC3D30C-D004-4445-A7C0-00B670B7652FQ33896523-627021A2-DD2F-4A7B-9DBF-C3DF19FE5144Q34290751-13B8878D-7EF3-4ADF-922D-88C2535DED18Q34350410-521CC611-40C6-4EA4-84BC-4E1BFD8D1E76Q34657557-4E64C5D5-CF39-4D32-8F03-8E3B7A840AF4Q34749218-55761CBE-25AC-4385-A294-14CF7EE94FABQ35153129-06E26D9B-74A0-4070-B7E9-F4D4C9AF3553Q35224581-1759DBC0-7423-49AF-BAFD-713D2F9B4660Q35928987-40656B2E-082C-4DA9-814F-ADC22FCABBE6Q35973632-E88A2ABC-80F4-4AE4-B8D5-1E0A7D12BDBAQ35980789-C3C9B7AA-3611-4B2E-9EB7-3EECAC74E96BQ36515071-BDB4F458-F186-4242-B14E-AD30D2164BC5Q36555611-44343E3D-2617-45FC-9DEA-77CDE5B6FDBAQ36576603-514D4101-64F4-48FC-863D-74DF440309BBQ36745227-2F0AA4FE-9EA4-4EF6-BCA8-8EC8D6CB6ED6Q36813547-0D650F39-23EB-45F9-8F3A-A84D43C3F36CQ36974205-A04FBD1B-FD1C-4799-9E10-AFF18C227FA1Q36986644-BE1B5BE5-85F5-4109-A2A0-41A0E075E5AAQ37014116-6C58EB00-9147-4947-99CD-39F416435889Q37215858-1B6205EC-23F0-408B-B849-70248FB61F4AQ38110971-CC7D9AFE-F426-4904-8362-2BBF7A635212Q38114911-0ED37559-BE08-4C41-95E0-0538B05883A3Q38126373-F3003E09-DAB0-47BA-A9A4-0CB2EDA157EBQ38156230-39C9A959-3B1B-4FD4-9520-9CFC581AD97DQ38165451-8D49032E-2F3B-48F9-A6E5-421D10881B3CQ38179732-036A6039-F318-440A-A191-70E2A598DA38Q38204769-0AADFD00-D555-468B-B7C9-58D0ABBC1037Q38205472-12E954B9-F3D3-42FC-B9C9-1E0DA06AEA51Q38235001-632F82BD-D900-424F-A0C5-C4EB5BFE4602
P2860
A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
A dendritic cell-based vaccine ...... control of HIV-1 replication.
@ast
A dendritic cell-based vaccine ...... control of HIV-1 replication.
@en
A dendritic cell-based vaccine ...... control of HIV-1 replication.
@nl
type
label
A dendritic cell-based vaccine ...... control of HIV-1 replication.
@ast
A dendritic cell-based vaccine ...... control of HIV-1 replication.
@en
A dendritic cell-based vaccine ...... control of HIV-1 replication.
@nl
prefLabel
A dendritic cell-based vaccine ...... control of HIV-1 replication.
@ast
A dendritic cell-based vaccine ...... control of HIV-1 replication.
@en
A dendritic cell-based vaccine ...... control of HIV-1 replication.
@nl
P2093
P2860
P50
P1476
A dendritic cell-based vaccine ...... control of HIV-1 replication.
@en
P2093
Alberto C Guardo
Cristina Gil
DCV2/MANON07-ORVACS Study Group
Jeffrey D Lifson
Josep M Gatell
Judit Dalmau
Montserrat Plana
Nuria Climent
Teresa Gallart
P2860
P304
P356
10.1126/SCITRANSLMED.3004682
P407
P577
2013-01-01T00:00:00Z